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Introduction {#sec1}
============

Lithium is the most commonly prescribed drug for the treatment of bipolar disorder. It also improves disease phenotypes in animal models of many clinical conditions including Alzheimer disease, depression, and stroke ([@bib16]). The effects of lithium on aging have been documented in yeast and *Caenorhabditis elegans*, with lithium extending lifespan ([@bib48], [@bib82], [@bib75], [@bib67]). The effects of lithium on *Drosophila* aging have previously been inconclusive, with demonstration of both positive and negative effects on survival ([@bib46], [@bib83]). Moreover, lithium concentration in the drinking water of a large Japanese population has been associated with reduced all-cause mortality ([@bib82]), suggesting that lithium may be a bona fide anti-aging drug. However, the mechanisms by which lithium acts in humans remain poorly understood.

In vitro studies have reported that lithium can protect against several forms of oxidative and xenobiotic stressors ([@bib36], [@bib64]), but in vivo evidence for such protective effects of lithium is lacking. Longevity has been extensively correlated with resistance to stress ([@bib51], [@bib57], [@bib13], [@bib22]). Transcriptomic analysis of interventions known to extend lifespan have identified particular genes likely to be involved in stress resistance ([@bib49], [@bib68]). Upregulation of the transcription factor cap'n'collar C (CncC, an NRF-2 homolog) has been shown not only to confer resistance to toxic compounds, but also to promote longevity in *C*. *elegans* and flies ([@bib78], [@bib71], [@bib23]). In flies and mammals, NRF-2/CncC is negatively inhibited through cytosolic sequestration and proteasomal degradation by the canonical Keap1 ([@bib27], [@bib55]). However, a second emerging upstream regulator of NRF-2/CncC is GSK-3, a well-documented target of lithium ([@bib33], [@bib27], [@bib17], [@bib28], [@bib8]). GSK-3 regulates NRF-2 by phosphorylation and nuclear exclusion, an effect that is evolutionarily conserved from invertebrates to mammals ([@bib61], [@bib2]). Interestingly, GSK-3 inhibition has been shown to phenocopy the effects of lithium for protection against xenobiotic stress in vitro ([@bib36], [@bib64]).

Activation of NRF-2/CncC produces hormetic effects on lifespan, such that at low level NRF-2/CncC activity extends lifespan while higher levels of activation limit it ([@bib47], [@bib42]). Interestingly a hormetic signature was recently reported for the survival of a mammalian cell line treated with lithium ([@bib70]), suggesting that lithium and GSK-3 inhibition could influence animal lifespan and stress resistance through activation of NRF-2.

Here we show that lithium supplementation in the diet can modulate longevity, stress resistance, and metabolism in *Drosophila* through the inhibition of GSK-3. Correspondingly, genetic downregulation of GSK-3 and lithium treatment are epistatic, suggesting a common molecular pathway. We also show that lithium and the genetic inhibition of GSK-3 promote xenobiotic stress resistance and lifespan extension through the activation of a transcriptional response mediated by CncC/NRF-2. Furthermore, lithium protects against a high-sucrose diet and acts through mechanisms that only partially overlap with those mediating lifespan extension by dietary restriction (DR). These findings demonstrate an alternative genetic and pharmacological target for the promotion of longevity and stress resistance, and emphasize the potential of pharmacological inhibitors of GSK-3 as viable anti-aging treatments.

Results {#sec2}
=======

Lithium Extends Healthy Lifespan in *Drosophila* {#sec2.1}
------------------------------------------------

To assess the role of lithium in *Drosophila* aging, we treated adult female flies with lithium chloride (LiCl) by supplementation in their food. Lithium treatment in the range of 1 to 25 mM resulted in lifespan extension, whereas higher doses (50--100 mM) shortened lifespan ([Figure 1](#fig1){ref-type="fig"}A). These effects of lithium treatment on lifespan extension were also observed in an independent genetic background ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and in males ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Thus, lithium treatment extended *Drosophila* lifespan independently of genetic background and sex.

To ensure that the increased lifespan observed with lithium supplementation was dependent on the addition of lithium itself, we treated flies with equivalent molar concentrations of sodium chloride (NaCl) and found no lifespan extension ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Thus, the pro-longevity effect of LiCl is specific to lithium and not its chloride counterion.

Interestingly, we observed that, unlike with many other genetic and pharmacological interventions (e.g., DR, insulin/IGF downregulation, rapamycin, or trametinib treatment), lithium did not reduce fecundity at life-extending doses or compromise feeding behavior ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). Moreover, it delayed locomotor decline at two concentrations that extend lifespan ([Figure 1](#fig1){ref-type="fig"}B). Thus, lithium promotes healthspan in adult *Drosophila* with limited side effects.

Lithium Extends Lifespan in Mid-life or with Short-Term Treatment in Young Flies {#sec2.2}
--------------------------------------------------------------------------------

To limit the side effects of long-term use, a drug that improves lifespan and healthspan will ideally do so with late-onset administration ([@bib15], [@bib40]). We therefore assessed the effect of commencing lithium treatment at older ages. Flies were switched onto food containing a range of lithium concentrations (1--75 mM) at 32 days of age ([Figure 1](#fig1){ref-type="fig"}C). Lower doses (1--25 mM) of lithium extended lifespan, whereas higher doses (50 and 75 mM) significantly reduced lifespan, similar to the dose-dependent effects we observed in younger flies.

We also tested whether transient lithium treatment early in life could increase lifespan. We therefore exposed young flies to 1 or 10 mM lithium for 15 days and then switched them to control food for the remainder of their lifespans. Early treatment with these doses of lithium extended lifespan ([Figure 1](#fig1){ref-type="fig"}D). Lithium treatment early in life, and for a transient period, can therefore increase survival later in life.

Lithium Alters Lipid Metabolism and Promotes Survival under a High-Sugar Diet {#sec2.3}
-----------------------------------------------------------------------------

Genetic and environmental interventions that extend lifespan often induce abnormalities in carbohydrate and lipid metabolism ([@bib6], [@bib80], [@bib37]). We therefore examined the effects of lithium on whole body trehalose, glycogen, and triglyceride levels. Following 15 days of lithium treatment, and over a wide range of lithium concentrations, we were unable to detect a significant change in the levels of either trehalose or glycogen ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). However, we observed a dose-dependent reduction in whole body triglycerides, the main lipid storage in flies ([@bib5], [@bib65]) ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}I). In keeping with the lowered triglyceride levels ([@bib5], [@bib79]), lithium treatment reduced survival under starvation conditions in a dose-dependent manner ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}J). Moreover, lithium also extended lifespan under dietary conditions that promote triglyceride accumulation ([@bib65]). Flies fed a high-sucrose diet were short lived and lithium was able to partially rescue this defect ([Figure 1](#fig1){ref-type="fig"}G) while completely blocking the increase in triglycerides observed with a sucrose-rich diet ([Figure 1](#fig1){ref-type="fig"}H). Therefore, lithium can extend lifespan under obesogenic dietary conditions.

Lithium and DR Extend Lifespan via Partially Overlapping Mechanisms {#sec2.4}
-------------------------------------------------------------------

We next investigated whether lithium treatment was acting as a DR mimetic. DR is a well-established anti-aging intervention that extends healthy lifespan in diverse species ([@bib18], [@bib24]), and some pharmacological and genetic interventions that extend lifespan have features of DR mimetics ([@bib31], [@bib18]). To determine whether lithium and DR extend lifespan by similar mechanisms, we assessed whether lithium could extend lifespan beyond the maximum achievable by DR. To maximize lifespan under DR, we varied the yeast concentration in the food while maintaining a constant concentration of sucrose ([@bib7]), resulting in a typical tent-shaped response, with peak lifespan at food containing a 1.0 yeast concentration ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A--S2D). If lithium treatment and DR share overlapping pathways, then lithium would not be able to further extend lifespan already maximized by DR ([@bib25], [@bib15]). All lithium doses tested significantly extended median lifespan in both the yeast condition that maximized lifespan (1.0 yeast; [Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}C) and under full feeding (2.0 yeast; [Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}D), with greatest extension of median lifespan with 10 mM lithium under full feeding. However, under reduced yeast concentrations that shorten lifespan (0.2 and 0.5 yeast), 10 mM lithium either significantly reduced lifespan ([Figure S2](#mmc1){ref-type="supplementary-material"}B) or did not confer a significant lifespan benefit ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Cox proportional hazards analysis showed a significant interaction between lithium and yeast concentrations for lifespan (interaction term p \< 0.0001). The extension of lifespan from lithium increased with the level of yeast in the fly diet, suggesting partially overlapping mechanisms to those of DR.

Lithium Extends Lifespan through Inhibition of GSK-3 {#sec2.5}
----------------------------------------------------

A well-known target of lithium is GSK-3 ([@bib54], [@bib33], [@bib21]). We therefore evaluated the phosphorylation status of the fly ortholog of GSK-3, Shaggy (Sgg), in response to lithium treatment. Lithium addition to the fly medium resulted in a dose-dependent increase in the inhibitory phosphorylation (Serine 9 or S9) of Sgg ([Figure 2](#fig2){ref-type="fig"}B). To evaluate the role of Sgg in lithium-mediated lifespan extension, we directly manipulated its activity in adult flies. Ubiquitous overexpression of wild-type or constitutively active Sgg (SggS9A) significantly reduced lifespan by ∼30% and 50%, respectively ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E). This reduction in lifespan was almost completely reversed by lithium treatment. Furthermore, RNAi-mediated reduction in *sgg* expression using two independent dsRNA-expressing transgenes significantly increased lifespan ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}F). Importantly, lithium was unable to further increase the lifespan of these *sgg* RNAi knockdown mutants flies ([Figure 2](#fig2){ref-type="fig"}D). Taken together, these findings suggest that Sgg/GSK-3 inhibition and lithium treatment increase lifespan by acting on the same downstream targets.

Lithium Activates the Cap'n'Collar C/NRF-2 Transcription Factor {#sec2.6}
---------------------------------------------------------------

To identify downstream mediators of lifespan extension by lithium and of GSK-3 inhibition, we analyzed the genome-wide transcript profiles of lithium-treated flies using microarrays. Genes encoding ribosomal proteins were among the most upregulated ([Figure 3](#fig3){ref-type="fig"}A) and downregulated ([Figure S3](#mmc1){ref-type="supplementary-material"}A) gene ontology (GO) categories in lithium-treated flies. This transcriptional response could underlie the translational repression following lithium treatment that has been previously observed in fission yeast and *Drosophila* heads ([@bib67]). In addition, five GO terms for genes encoding enzymes in the detoxification pathway were also in the ten most upregulated categories ([Figure 3](#fig3){ref-type="fig"}A).

The responses to xenobiotics and oxidative stress in *Drosophila* are regulated by the transcription factors dFOXO, CncC, and DHR96 ([@bib62], [@bib72], [@bib77], [@bib30], [@bib8]). We therefore assessed whether the transcriptional responses to activation of these transcription factors overlapped with that of lithium treatment. The transcriptomic response to lithium did not overlap with that of dFOXO-dependent or -independent transcriptional regulation downstream of IIS ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C) ([@bib1]). Furthermore, although we detected a significant overlap in the transcriptional signatures of lithium and DHR96 ([@bib35]), they did not share the same directionality ([Figure S4](#mmc1){ref-type="supplementary-material"}). However, we found a significant overlap ([Figure 3](#fig3){ref-type="fig"}B) between the genes that were upregulated by lithium and *cncC* overexpression ([@bib52]), but not between genes downregulated by both treatments ([Figure S5](#mmc1){ref-type="supplementary-material"}A), suggesting that lithium might activate a CncC transcriptional response downstream of GSK-3. The barbiturate phenobarbital activates CncC and induces a similar transcriptional response to that of *cncC* overexpression ([@bib52]). We therefore analyzed the overlap between the transcriptional profiles induced by lithium and phenobarbital treatment, and again found a significant overlap ([Figure 3](#fig3){ref-type="fig"}B) between upregulated, but not downregulated, genes ([Figure S5](#mmc1){ref-type="supplementary-material"}B). The genes upregulated in common between lithium treatment, phenobarbital treatment and *cncC* overexpression ([Figures 3](#fig3){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}C) encoded enzymes that participate in all three phases of xenobiotic metabolism ([Figure 3](#fig3){ref-type="fig"}C). To further confirm the activation of CncC by lithium, we used a previously generated CncC reporter that responds to both chemical and genetic inducers of CncC ([@bib71]). Flies carrying the GstD-eGFP CncC reporter showed a dose-dependent increase in GFP expression with increasing concentrations of lithium ([Figure 3](#fig3){ref-type="fig"}D). Taken together, our results suggest that lithium activates CncC to upregulate the expression of genes in the detoxification pathway.

Lithium Induces Lifespan-Extension, Hormesis, and Protection against Xenobiotics via CncC-Dependent Mechanisms {#sec2.7}
--------------------------------------------------------------------------------------------------------------

We next assessed whether CncC activity is required for the pro-longevity effects of lithium. Ubiquitous, RNAi-mediated knockdown of *cncC* expression blocked the lifespan extension of 1 to 10 mM lithium, but was detrimental to survival in flies treated with 25 mM lithium, the highest dose that extends lifespan under basal conditions, albeit to a lesser extent ([Figure 4](#fig4){ref-type="fig"}A). Thus, lithium treatment requires CncC activity to confer its longevity benefits.

Because CncC/NRF-2 can induce hormesis ([@bib47], [@bib42]), we assessed whether lithium can also do this. To test for a hormetic effect of lithium at low doses, we pre-treated flies with a range of concentrations of lithium and then challenged them with a toxic dose of 500 mM. Most pre-treatment doses of lithium induced subsequent resistance to the toxic dose ([Figure 4](#fig4){ref-type="fig"}B). To assess whether the hormetic response of lithium was mediated by CncC, we knocked down expression of *cncC* using RNAi, and treated the flies with 1--25 mM lithium. Reduction in *cncC* expression completely blocked the hormetic response induced by 10 mM lithium pre-treatment, and significantly reduced the effect of 25 mM lithium ([Figure 4](#fig4){ref-type="fig"}C).

We next assessed the ability of lithium pre-treatment to protect against other xenobiotics. Flies pre-treated with increasing concentrations of lithium ranging from 1 to 100 mM were significantly resistant to a toxic concentration of phenobarbital, with lithium doses between 1 and 75 mM almost doubling survival ([Figure 4](#fig4){ref-type="fig"}D). Lower doses of lithium also protected against a toxic dose of the anti-malarial drug, chloroquine ([Figure S5](#mmc1){ref-type="supplementary-material"}D; 1--10 mM), and the pesticide paraquat ([Figure 4](#fig4){ref-type="fig"}E). Thus, low to intermediate concentrations of lithium protect against xenobiotic toxicity. To determine the role of CncC activity in lithium-mediated protection against phenobarbital, we used RNAi to knock down expression of *cncC*, which sensitized the flies to phenobarbital and completely abrogated the protection against phenobarbital afforded by lithium supplementation ([Figure 4](#fig4){ref-type="fig"}F). Thus, CncC is at least partly responsible for the hormetic effect induced by low-level treatment with lithium.

To confirm that Sgg, upstream of CncC, is also necessary for the resistance to xenobiotic stress ([@bib8], [@bib17], [@bib28]), we assessed the effect of ubiquitous overexpression of wild-type *sgg* or the constitutively active Sgg(S9A) on xenobiotic resistance. Both significantly sensitized flies to phenobarbital ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}E). We confirmed that *sgg* or *sgg(S9A)* overexpression regulated CncC by showing significantly lower levels of *MRP* and *keap1* ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}F), both CncC target genes. Correspondingly, RNAi-mediated knockdown of *sgg* resulted in resistance to phenobarbital ([Figure 5](#fig5){ref-type="fig"}C), and paraquat ([Figure S5](#mmc1){ref-type="supplementary-material"}G). An increase of mRNA levels of *cncC*, *keap1*, and *gstD2* confirmed that CncC was active in *sgg* knockdown flies ([Figure 5](#fig5){ref-type="fig"}D). Thus, increased Sgg activity sensitizes against xenobiotic stressors, whereas its inhibition protects against them.

Lifespan and Stress Resistance Depend on the Degree of Activation of CncC by Keap1 and Lithium Treatment {#sec2.8}
--------------------------------------------------------------------------------------------------------

In addition to activating CncC by repressing Sgg/GSK-3, lithium could potentially increase CncC activity by inhibiting its canonical repressor Keap1 ([@bib17], [@bib55]). Hence, we analyzed the interaction between lithium treatment and Keap1. Overexpression of Keap1, which inhibits CncC activity in vivo ([@bib71]), was unable to prevent the lifespan-extending properties of lithium ([Figure 6](#fig6){ref-type="fig"}A), suggesting that the longevity effect of lithium treatment is independent of Keap1. Next, we analyzed the interaction of loss of Keap1 and lithium treatment. We generated a deletion of the *keap1* coding sequence by P-element-mediated male recombination using a previously described P-element insertion line ([@bib71]) ([Figure 6](#fig6){ref-type="fig"}B). The *keap1* deletion (*keap1*^*Del*^) was homozygous lethal, but activated CncC 4-fold in the heterozygous state, as measured by the CncC reporter ([Figure 6](#fig6){ref-type="fig"}C). Lithium treatment of the *keap1*^*Del*^ flies further activated CncC ([Figure 6](#fig6){ref-type="fig"}C). We next tested whether this effect on CncC activation protected against paraquat and lithium toxicity. *keap1*^*Del*^ flies were significantly resistant to both paraquat and lithium ([Figures 6](#fig6){ref-type="fig"}D and 6E), and pre-treatment with lithium further protected them. We confirmed these findings using a previously described heterozygous loss-of-function mutation in the *keap1* gene (*keap1*^*EY5*^) ([@bib71]) ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Thus, the combination of loss of *keap1* and lithium treatment further protected against paraquat and lithium-induced toxicity, suggesting that stronger CncC activation results in greater protection against these xenobiotics.

We subsequently evaluated the interaction between loss of *keap1* and lithium treatment for longevity. Survival analysis showed that the lifespan of *keap1*^*Del*^ mutant flies was indistinguishable from controls, but that addition of 1 mM lithium marginally, yet significantly, extended lifespan ([Figure 6](#fig6){ref-type="fig"}F). Increasing the dose of lithium to 10 mM restored longevity to control levels. The *keap1*^*EY5*^ mutant flies showed a significant lifespan extension ([Figure 6](#fig6){ref-type="fig"}G). However, supplementation of either 1 or 10 mM lithium to the *keap1*^*EY5*^ mutant shortened lifespan in a dose-dependent manner. These results suggest that the level of activation of CncC that maximizes extension of lifespan is considerably lower than that which maximizes protection against toxic doses of lithium and paraquat.

Lithium Does Not Induce or Require Autophagy to Promote Longevity {#sec2.9}
-----------------------------------------------------------------

Activation of autophagy has been proposed as a mechanism for the beneficial effects of lithium ([@bib63]). We therefore analyzed the induction of autophagy by LC3-I/LC3-II (Atg8 in *Drosophila*) levels without detecting statistically significant changes. Indeed, there was a tendency for lower LC3-I that did not reach statistical significance ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Moreover, lithium treatment was able to extend the lifespan of flies with autophagy defects due to heterozygous loss of *atg1* ([Figure S7](#mmc1){ref-type="supplementary-material"}B) ([@bib38]). Thus, taken together our results do not immediately support a role for autophagy in the pro-longevity effects of lithium treatment, and strengthen our conclusion that they are mediated through the inhibition of GSK-3 and the subsequent activation of CncC/NRF-2 ([Figure 7](#fig7){ref-type="fig"}). However, it remains possible that induction of autophagy occurs in *atg1*-deficient flies, or that lithium induces autophagy in a tissue-specific manner.

Discussion {#sec3}
==========

Lithium Acts as a Pro-longevity Drug {#sec3.1}
------------------------------------

Drug repurposing is the most promising approach for developing pharmacological agents to improve healthy aging. So far, two medically approved drugs, metformin and rapamycin, have been reported to promote longevity and provide health benefits across species from invertebrates to mammals ([@bib18], [@bib41], [@bib58]). We and others have shown that lithium can extend lifespan in fission yeast, *C*. *elegans*, and *Drosophila* ([@bib48], [@bib46], [@bib67]). We also showed that this effect was common between two different laboratory strains and, unlike other interventions that seem to be more effective in females ([@bib3]), lithium similarly extended lifespan in both sexes.

Lifespan-extending drugs can often act like DR mimetics ([@bib41], [@bib31]); hence, it was important to determine whether lithium was acting in a similar manner. While low doses of lithium were able to extend lifespan at all dietary levels tested, median lifespan extension was greatest under full feeding conditions. Our data thus suggest that lithium and DR act via partially overlapping mechanisms and confirms the observation made in *C*. *elegans* that lithium extends lifespan of *eat-2* mutants ([@bib48]), a genetic model of DR in worms. Lithium also extended the lifespan of flies fed a diet enriched with sucrose, possibly by modulating lipid metabolism ([@bib73], [@bib53], [@bib34], [@bib69]). However, the role of CncC in modulating the triglyceride phenotype of lithium remains to be explored. Overall, our observations strongly suggest that lithium is a pro-longevity drug capable of extending lifespan at low doses independent of sex and genetic background, and under a variety of dietary conditions.

Lithium Toxicity, Hormesis, and Stress Resistance {#sec3.2}
-------------------------------------------------

In humans, the therapeutic window for lithium treatment of bipolar disorder lies between 0.5 and 1 mM in serum, whereas concentrations of 1.5 mM and above severely increase the risk of tissue damage ([@bib43]). Previous work in *Drosophila* suggests that the dose range at which we observed lifespan extension (0.5--25 mM) translates to *Drosophila* tissue concentrations below 0.5 mM ([@bib19]). As previously reported for *C*. *elegans* and *Drosophila* ([@bib48], [@bib83]), concentrations above 50 mM were highly toxic.

Drug interventions to promote healthy lifespan are less likely to have side effects if started late in life ([@bib15]). Only a handful of drugs approved by the US Food and Drug Administration, namely rapamycin, metformin, and the Ras inhibitor trametinib, induce lifespan extension when commenced at later ages in model organisms ([@bib26], [@bib10], [@bib44], [@bib66]). We found that lithium extends lifespan when first administered in mid-late life. In humans, long-term treatment with lithium for psychiatric disorders is associated with progressive and permanent renal damage ([@bib43]). We showed that short treatment periods in *Drosophila*, 15 days during early adulthood, are sufficient to prolong life. Taken together, our data suggest that when testing lithium as a pro-longevity drug in mammals, lower doses than those used in psychiatric disorders are likely to be sufficient, and other strategies such as alternate-day dosing or transient treatment periods (either early or late in life), may be sufficient to reduce undesirable side effects and maximize the potential health benefits.

Interestingly, doses of lithium that shortened lifespan were protective against certain forms of xenobiotic stress. In vitro studies in mammalian cells have shown that lithium, and other GSK-3 inhibitors, protect against cell death caused by rotenone-induced oxidative stress ([@bib36]), glutamate excitotoxicity, and H~2~O~2~ ([@bib64]). This is likely mediated through a hormetic response ([@bib70]), in this case orchestrated by NRF-2 activation. We observed that while simultaneous activation of CncC by loss of Keap1 and lithium treatment is additive and confers greater stress resistance to xenobiotics, the threshold for lifespan extension is perhaps considerably lower. A similar situation has been observed in *C*. *elegans* in which strong activation of the endoplasmic reticulum unfolded protein response conferred stress resistance benefits, while shortening lifespan ([@bib76]). Our findings thus suggest that while NRF-2 activation either by loss of Keap1 or inhibition of GSK-3 is beneficial for longevity and stress resistance, at low levels of activation, stronger induction is detrimental for lifespan. This suggests that the hormetic benefits of lithium are more likely to occur at low levels under basal non-stress conditions ([@bib11]). Hence, when testing for GSK-3 inhibitors or NRF-2 activators in modulating animal (and especially mammalian) aging, the degree of NRF-2 activation within the hormetic curve will determine positive or negative longevity outcomes. Future work studying the convergence of the salutary and damaging effects of lithium will aid in understanding to what extent the molecular mechanisms are shared ([@bib12], [@bib14], [@bib22]). Additionally, our microarray analysis was performed in heads and thoraces; therefore, it remains to be explored to what extent systemic or localized activation of NRF-2 modulates longevity, stress resistance, and lipid metabolism at the tissue level ([@bib20]).

GSK-3 and NRF-2 as Drug Targets for Aging {#sec3.3}
-----------------------------------------

Complete absence of GSK-3 in *C*. *elegans*, *Drosophila*, and mice shortens lifespan or prevents development ([@bib29], [@bib48], [@bib9]), while moderate inhibition has been associated with most of its positive effects ([@bib4]). GSK-3 is upregulated in many disease states, including neurodegeneration, diabetes, inflammatory conditions, and some cancers ([@bib74]). We have shown that adult-specific genetic manipulation of the fly ortholog of GSK-3, Sgg, affects longevity. Downregulation of Sgg prolonged lifespan and lithium was unable to further extend the lifespan, suggesting that lithium and inhibition of Sgg act through a common molecular pathway to extend lifespan.

In *C*. *elegans* and mammalian cells, GSK-3 directly interacts with NRF-2 to repress its activity, independently of Keap1 ([@bib2], [@bib61], [@bib60], [@bib56]). Therefore, we hypothesized that lithium might act via Sgg/GSK-3, to de-repress CncC, the fly ortholog of NRF-2 and activate the oxidative and xenobiotic stress transcriptional signature ([@bib2], [@bib28]), which in turn would induce a CncC/NRF-2-dependent protective response ([@bib32], [@bib8]). GO enrichment analysis identified a transcriptional signature that indeed suggested that lithium acts via CncC/NRF-2. CncC activity was indispensable for the lifespan extension conferred by lithium. In keeping with our results, work in rodents and mammalian cell lines has shown that lithium treatment and GSK-3 inhibition activate NRF-2 ([@bib39], [@bib59]). Because activation of CncC/NRF-2 modulates longevity in *C*. *elegans* and *Drosophila* ([@bib78], [@bib71], [@bib23]), our results provide evidence that GSK-3 is a viable therapeutic target to promote longevity via activation of NRF-2.

To date, the only GSK-3 inhibitor approved for human use is lithium ([@bib81], [@bib50], [@bib45]). However, researchers and pharmaceutical companies have developed more selective GSK-3 inhibitors, some of which have already entered the early stages of clinical trials for obesity, Alzheimer disease, and progressive supranuclear palsy ([@bib21]). Our results call for a reassessment of the potential use of GSK-3 inhibitors and NRF-2 activators as potential anti-aging compounds.

Experimental Procedures {#sec4}
=======================

Fly Stocks and Husbandry {#sec4.1}
------------------------

The *w*^*1118*^ stock was obtained from Bloomington *Drosophila* Stock Center. The control white *Dahomey* (*w*^*Dah*^) stock has been maintained in large population cages with overlapping generations since 1970. The *w*^*Dah*^ stock was initially derived by incorporation of the *w*^1118^ mutation into the outbred *Dahomey* background by backcrossing ([@bib7]). Further details concerning fly mutants can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Lithium Treatment {#sec4.2}
-----------------

LiCl (Sigma) or NaCl (Sigma) were dissolved in ddH~2~O at a concentration of 5 M before supplementing to the medium. Equivalent volumes of vehicle were supplemented to the medium to compensate for dilution.

Dietary Restriction Protocol {#sec4.3}
----------------------------

The DR protocol was performed as described previously ([@bib7]).

Statistical Analyses {#sec4.4}
--------------------

Statistical analyses were performed using Excel, GraphPad Prism, or JMP software version 9 (SAS Institute). Survival experiments were analyzed using log rank test. Other data were tested by one-way analyses of variance (ANOVA) and planned comparisons of means were made using Tukey-Kramer HSD test. Cox proportional hazards analysis was performed to compare interactions for survival.
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![Lithium Regulated Longevity and Metabolism in *Drosophila*\
(A) Lithium extended lifespan of *w*^*Dah*^*Drosophila* females (n = 160 flies per condition) at concentrations between 1 and 25 mM (+16% and +18% median and maximum lifespan extension; p \< 0.001), but resulted in a dose-dependent reduction in lifespan at concentrations between 50 and 100 mM (p \< 0.001).\
(B) Lithium treated female *w*^*1118*^ flies showed a significant improvement and protection against age-related locomotor decline (p \< 0.01, two-way ANOVA for 10 mM).\
(C) Lithium extended lifespan of aged, 32-day-old female *w*^*Dah*^ flies at concentrations from 1 to 25 mM (30 days later than in [Figure 1](#fig1){ref-type="fig"}A): 1 mM extended median lifespan by 5% (4 days) and maximum lifespan by 13% (8 days; p \< 0.05); 10 and 25 mM lithium increased median lifespan by 9% (6 days); 10 mM increased maximum lifespan by 4.5% (3.5 days); wherease 25 mM lengthened it by 8% or 6 days (p \< 0.01); and 50 and 75 mM significantly shortened lifespan (p \< 0.01). n = 150 flies per condition.\
(D) Brief treatment with lithium for 15 days early in adulthood extended lifespan of female *w*^*Dah*^ flies (p \< 0.05 for 1 mM and p \< 0.01 for 10 mM; n = 150 flies per condition).\
(E) Lithium induced a dose-dependent reduction in triglyceride levels. Bars represent means of six replicas of five flies per condition ± SEM. ^∗^p \< 0.01, ^∗∗^p \< 0.001.\
(F) Female *w*^*Dah*^ flies pre-treated with lithium for 15 days were subsequently sensitive to starvation in a dose-dependent manner (n = 90 flies per condition).\
(G) Lithium treatment significantly extended the lifespan of *w*^*1118*^ female flies exposed to a four times higher sucrose concentration (2g/L; p \< 0.001; n = 120 flies per condition).\
(H) The increase of triglycerides observed on a high-sucrose diet was completely blocked after 15 days of treatment with 1 mM lithium. Bars represent means of six replicas of five *w*^*1118*^ female flies per condition ± SEM. ^∗^p \< 0.01.](gr1){#fig1}

![Lithium Extended Lifespan beyond Dietary Restriction by Inhibiting Sgg/GSK-3\
(A) Median lifespans at different lithium concentrations (0, 1, 2.5, 5, or 10 mM) are plotted for four different yeast concentrations (0.2×, 0.5×, 1.0×, and 2.0× yeast): 1--5 mM lithium extended lifespan under all dietary conditions tested. Although 10 mM lithium prolonged life at 1.0× and 2.0×, it showed no effect at 0.2× and significantly shortened lifespan at 0.5× yeast. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, from 0 lithium; n = 160 flies per condition. Complete survival curves are shown in [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D.\
(B) Lithium treatment for 15 days significantly increased the inhibitory phosphorylation of Sgg/GSK-3 in a dose-dependent manner. Bars represent means of triplicates of ten flies per biological repeat ± SEM, ^∗^p \< 0.05, ^∗∗^p \< 0.01.\
(C) Ubiquitous overexpression of wild-type *sgg* significantly shortened lifespan (p \< 0.001) and this was partially rescued by lithium treatment at two concentrations (10 and 25 mM; p \< 0.001). See [Figure S2](#mmc1){ref-type="supplementary-material"}E for the interaction of *sgg(S9A)* and lithium treatment on lifespan.\
(D) Ubiquitous RNAi-mediated downregulation of *sgg* extended lifespan (p \< 0.001) and no further extension occurred when the flies were treated with 1 or 5 mM lithium (p \> 0.05), whereas 10 mM lithium treatment restored the lifespan to control levels (p \> 0.05), and 25 mM was significantly toxic (p \> 0.05). See [Figure S2](#mmc1){ref-type="supplementary-material"}F for lifespan extension obtained with an independent RNAi line.](gr2){#fig2}

![Lithium Activated a Transcriptional Response Similar to that of CncC/NRF-2\
(A) Ten most significantly upregulated GO categories induced by lithium treatment of *w*^*1118*^ female flies. See [Figure S3](#mmc1){ref-type="supplementary-material"}A for downregulated GO categories.\
(B) Lithium treatment of *w*^*1118*^ females flies induced a transcriptional response that significantly overlapped with that induced by *cncC* overexpression (p = 7.83 × 10^−8^) or phenobarbital treatment (p = 3.85 × 10^−14^) ([@bib52]). Heatmap showing the 57 genes most significantly changed by lithium or phenobarbital treatment and overexpression of *cncC*.\
(C) Genes upregulated by lithium treatment mapped to the three phases of the xenobiotic detoxification pathway in flies.\
(D) Lithium treatment of *w*^*Dah*^ female flies upregulated Gst-D protein levels. Bars represent means of triplicates of ten flies per condition ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01.](gr3){#fig3}

![Lithium-Induced Xenobiotic Resistance and Longevity Were Mediated by CncC\
(A) Ubiquitous knockdown of *cncC* blocked lifespan extension by lithium.\
(B) Pre-treatment with increasing concentrations of lithium protected against a subsequent toxic dose of lithium (500 mM; p \< 0.01 for doses from 10 to 100 mM; p \< 0.05 for 1 mM).\
(C) Ubiquitous downregulation of *cncC* blocked the protective effect of 10 mM lithium pre-treatment against a subsequent toxic dose and partially blocked the protective effect of 25 mM lithium pre-treatment.\
(D) 1 to 100 mM lithium pre-treatment protected against a 6% phenobarbital (p \< 0.001 for all doses).\
(E) Lithium pre-treatment (for 15 days) protected against the herbicide paraquat in a dose-dependent manner (p \< 0.001 for all doses, with maximal protection at 50 mM).\
(F) RNAi-mediated downregulation of *cncC* completely blocked the protective effect of lithium against phenobarbital.](gr4){#fig4}

![Reduced Activity of GSK-3 Increased Resistance to Xenobiotics\
(A) Ubiquitous overexpression of wild-type *sgg* significantly (p \< 0.05) reduced survival under xenobiotic stress with phenobarbital. n = 75 flies per condition.\
(B) Overexpression of wild-type *sgg* significantly reduced multidrug-resistance like protein 1 (*MRP*) mRNA levels (p \< 0.05, paired t test), whereas non-significant trends were detected for glutathione S transferase D2 (*gstD2*) and *cncC* mRNA levels (p \> 0.05). A non-significant increase of *keap1* mRNA levels was observed.\
(C) RNAi-mediated knockdown of *sgg* protected against phenobarbital stress (p \< 0.001). n = 75 flies per condition.\
(D) Knockdown of *sgg* increased mRNA levels of *cncC*, *keap1* and *gstD2* (p \< 0.05), while a non-significant increase was observed for *MRP* mRNA levels.](gr5){#fig5}

![Higher Activation Levels of CncC Promote Xenobiotic Resistance but Not Lifespan\
(A) Overexpression of *keap1* did not prevent the lifespan-modulatory effects of lithium treatment. n = 150 flies per condition.\
(B) Schematic of the *keap1* gene showing the portion deleted in the *keap1*^*Del*^ mutant (top) and agarose gel showing start and end of P-element disrupting *keap1* coding sequence in the *keap1*^*Del*^ mutant (bottom).\
(C) Combination of heterozygous deletion of *keap1* and lithium treatment showed a greater activation of CncC than on their own. Bars represent means of four replicas of five flies per repeat ± SEM. ^∗∗^p \< 0.01.\
(D) Deletion of *keap1* in flies treated with lithium showed greater protection against paraquat than either treatment on its own, with maximal effects observed at 25 mM (p \< 0.001).\
(E) The *keap1* deletion protected against toxic concentrations of lithium (500 mM), and this protection was augmented with lithium pre-treatment (p \< 0.01).\
(F) Deletion of *keap1* did not extend lifespan: 1 mM lithium (p \< 0.05), but not 10 mM (p \> 0.05), treatment of *keap1* flies resulted in a small but significant extension. n = 150 flies per condition.\
(G) *keap1*^*EY5*^ mutant flies showed significant lifespan extension (p \< 0.001), that was dose-dependently abolished (p \> 0.05) by lithium, likely as a result of over-activation of CncC. n = 150 flies per condition.](gr6){#fig6}

![Lithium Regulates Longevity, Metabolism, and Stress Resistance by Inhibiting GSK-3 and Activating NRF-2\
(A) Summary of findings with lithium for longevity, stress resistance, starvation, and triglyceride levels.\
(B) Proposed model showing the mechanism by which lithium, Sgg/GSK-3, and CncC/NRF-2 act in the same pathway to modulate longevity and xenobiotic resistance.](gr7){#fig7}
